Cisplatin / paclitaxel chemotherapy in the treatment of ovarian cancer drug side effects
Treatment of ovarian cancer chemotherapy new program Researchers reported that the joint use of both cisplatin and paclitaxel chemotherapy drug for ovarian cancer achieved better clinical remis...
Intraperitoneal chemotherapy should be first-line therapy in ovarian cancer A large number of pre-clinical data and the right abdominal anatomy, physiology and biology of ovarian cancer have suggested that understan...
Whitney physicians that cisplatin / paclitaxel chemotherapy in the treatment of ovarian cancer treatment should become the new standard.
Carboplatin / taxol treatment programs, and the current phase III epithelial ovarian tumors standard chemotherapy - cisplatin / paclitaxel, the same as its efficacy, toxicity small. Experts believe that the program should become a new standard treatment programs.
Combination of paclitaxel and cisplatin, paclitaxel must be sustained 24-hour infusion, and Taxol and carboplatin compatibility, 3-hour infusion of paclitaxel can, thus reducing low toxic side effects to a large extent.
According to Canada “Medical Post” reported that the Pennsylvania Cancer Center Whitney FoxChase physicians recently led a Phase III clinical trial to compare the efficacy of two different programs. In 790 cases (63% of the overall residual tumor) were randomized to receive two programs, cisplatin plus paclitaxel 75mg/m2 135mg/m2 (continuous 24-hour infusion) or carboplatin (AUC7.5) plus paclitaxel 175mg/m2 (3 hours continuous infusion). A 21-day cycle of chemotherapy, repeat six courses. All the cases were conducted surgery, residual tumor lesions no case more than 1cm. The average age of nearly 60 years, the study group of patients without age restrictions.
The researchers found that carboplatin / paclitaxel group condition is the relative risk of 0.86, indicating dangerous decline. Gynecologic Oncology Institute, in the group, Bernard physicians reported the results of this study, and that toxicity studies also carboplatin / paclitaxel group beneficial. According to the study, Julius and physicians have established a new standard treatment program that abandoning the old cisplatin / paclitaxel, carboplatin read / Taxol. The study found that cisplatin / paclitaxel in Group IV of inhibiting IL, gastrointestinal reactions, fever and more metabolic disorder, and carboplatin / paclitaxel in Group IV of platelet inhibition and more pain.
In Europe have done two smaller studies were similar to the research, although the chemotherapy drug delivery methods vary, no specific target cytoreductive surgery than satisfied with the stage III patients, but also came to a similar conclusion. Because of this type of patients with the best long-term survival rates, physicians in the study Whitney, the choice for these patients as research subjects. The relatively good prognosis, fewer side effects and drug injection method is simple, Julius physician added: “I would like to carboplatin / paclitaxel has become standard treatment.”
Although not on the objective of the study on “second exploration of” (second_looksurgery, SLS, after referred to as “two Exploration”) is also analyzed. In choosing randomized, physicians had already decided whether to do with the “two exploration.” A total of 395 cases to the “two exploration”, 403 cases done, “two exploration.” Cisplatin / Taxol group and carboplatin / paclitaxel “two exploration” negative rate of 45% and 51.5%. The study, from the course of progress, was found to have received “two exploration” of the patients have any benefit. This is so far the “two exploration” one of the largest prospective study. Conventional conclusion is not to encourage the “two exploration.
The FDA approved a new therapy for ovarian cancer paclitaxel (Taxol) therapy Abstract: The FDA approved a new treatment of advanced ovarian cancer on the first line of the short-term treatment programs, in the treatm...
Taxol and carboplatin Joint effective treatment of advanced ovarian cancer According to an obstetrics and gynecology oncology groups (GOG) study said that the smaller Phase III epithelial ovarian cancer patients, ca...
Ovarian cancer treatment A benign ovarian tumors young patients affected Annex tumor resection or stripped of. If both bilateral ovarian tumors, should fight to reta...
Ovarian cancer drug cisplatin resistance Clinical Solutions Ovarian cancer mortality first Habitat gynecologic malignancies, as misprision of onset, 70% of patients when treatment is already advanced....
Interventional therapy of ovarian cancer Ovarian cancer is one of the female genital common tumor, the treatment of surgical resection mainly, but because of the lack of effective ...
Previous accept carboplatin multidrug chemotherapy in patients with recurrent ovarian cancer Carboplatin and Paclitaxel weekly therapy is safe and effective Kikuchi, the Japanese report, have received platinum multidrug chemotherapy for recurrent ovarian cancer Japanese women, a weekly carboplati...
Tags: age, cancer, carboplatin, cases, cause, chemotherapy, cisplatin, clinical, drug, early, eat, ert, exploration, grams, group, infusion, injection, method, ovarian, paclitaxel, pain, patients, prognosis, rate, residual, risk, second, study, surgery, survival, taxol, therapy, toxicity, treatment, tumor, tumors